cisplatin + carboplatin + pemetrexed + durvalumab + tremelimumab

This is a combination regimen consisting of two platinum-based chemotherapies (cisplatin and carboplatin), an antifolate antineoplastic agent (pemetrexed), and two immune checkpoint inhibitors (durvalumab, a PD-L1 inhibitor, and tremelimumab, a CTLA-4 inhibitor). The combination is used as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) without EGFR or ALK mutations. The mechanism of action involves direct cytotoxicity from the chemotherapeutic agents and enhanced anti-tumor immune response via dual checkpoint blockade. This regimen was evaluated in the Phase III POSEIDON trial, which demonstrated improved progression-free survival and overall survival compared to chemotherapy alone[1][2][5][7][8].